though i do find it strange that many other products are sold as food supplements that contain molecules that have been scientifically proven to be of benefit, as yet CBD has not, at least in the case of GW clinical trials - to be pedantic about it ;)
New Cannabis Ventures reported yesterday that the Food & Drug Administration (FDA) had issued 8 warning letters to marketers of hemp-derived CBD products, and the FDA actions are sending a chill throughout the industry. New Hope 360, which covers the healthy lifestyle industry and puts on the huge Natural Products Expos, summarized the implications and industry reaction, suggesting that the enforcement of rules regarding health claims could lead to a situation where CBD is available only in pharmacies as a prescribed drug.
The fact that GW Pharma (NASDAQ: GWPH) conducted clinical trials on a CBD product in 2007 (Sativex) is now an issue that hangs over the industry, as the FDA is citing the trials as a reason that products with CBD can no longer be called “supplements”. A spokesperson from GW Pharma stated that the company is not planning on the FDA to shut down the makers of CBD products.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.